- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
826
Companies which are more than 50% undervalued based on analyst price target.
826 companies
Achieve Life Sciences
Market Cap: US$81.5m
A clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
ACHV
US$2.48
7D
-6.1%
1Y
-48.4%
Planet 13 Holdings
Market Cap: CA$113.8m
Planet 13 Holdings Inc., together with its subsidiaries, cultivates and provides cannabis and cannabis-infused products for medical and retail cannabis markets in the United States.
PLTH
CA$0.36
7D
-10.0%
1Y
-56.1%
Climb Bio
Market Cap: US$80.4m
A clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
CLYM
US$1.24
7D
-0.8%
1Y
-85.3%
Genenta Science
Market Cap: US$79.4m
A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
GNTA
US$4.17
7D
-0.2%
1Y
18.8%
Agenus
Market Cap: US$79.1m
A clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.
AGEN
US$3.50
7D
13.3%
1Y
-68.4%
Corbus Pharmaceuticals Holdings
Market Cap: US$78.9m
A biopharmaceutical company, develops products to defeat serious illness.
CRBP
US$7.16
7D
-3.5%
1Y
-83.3%
Satellos Bioscience
Market Cap: CA$109.5m
A biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.
MSCL
CA$0.64
7D
-5.9%
1Y
33.3%
Invivyd
Market Cap: US$77.5m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$0.84
7D
45.6%
1Y
-64.6%
Adaptimmune Therapeutics
Market Cap: US$77.2m
A commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
ADAP
US$0.30
7D
-2.5%
1Y
-74.8%
Unité de Fabrication des Médicaments
Market Cap: د.ت233.3m
Unité de Fabrication des Médicaments S.A.
UMED
د.ت7.29
7D
0.3%
1Y
2.7%
Paradigm Biopharmaceuticals
Market Cap: AU$120.7m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.31
7D
3.3%
1Y
14.8%
Adagene
Market Cap: US$75.4m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$1.70
7D
4.9%
1Y
-23.8%
Simply Better Brands
Market Cap: CA$105.0m
Operates as a consumer products company with diversified assets in the plant-based and wellness consumer product categories in Canada.
SBBC
CA$0.97
7D
6.6%
1Y
136.6%
Zura Bio
Market Cap: US$74.9m
A clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
ZURA
US$1.24
7D
-13.9%
1Y
-74.1%
CytomX Therapeutics
Market Cap: US$74.8m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$2.13
7D
121.6%
1Y
12.7%
Inozyme Pharma
Market Cap: US$74.2m
A clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.
INZY
US$1.18
7D
-20.8%
1Y
-73.8%
Telomir Pharmaceuticals
Market Cap: US$74.1m
A pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism.
TELO
US$2.51
7D
-2.3%
1Y
-62.3%
CervoMed
Market Cap: US$73.9m
A biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
CRVO
US$9.10
7D
-8.5%
1Y
-62.8%
Veru
Market Cap: US$73.8m
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
VERU
US$0.52
7D
2.2%
1Y
-60.8%
Cibus
Market Cap: US$73.8m
An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.
CBUS
US$2.43
7D
15.7%
1Y
-87.0%
Sutro Biopharma
Market Cap: US$73.6m
Operates as a oncology company.
STRO
US$0.87
7D
-17.1%
1Y
-79.4%
Milestone Pharmaceuticals
Market Cap: US$73.6m
A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
MIST
US$1.20
7D
-9.8%
1Y
-29.4%
Jushi Holdings
Market Cap: US$72.8m
A vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for the medical and adult-use markets in the United States.
JUSH.F
US$0.35
7D
-14.1%
1Y
-46.5%
MediciNova
Market Cap: US$72.1m
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MNOV
US$1.44
7D
-4.0%
1Y
-5.3%
Caribou Biosciences
Market Cap: US$72.0m
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
CRBU
US$0.82
7D
-4.7%
1Y
-77.9%
TScan Therapeutics
Market Cap: US$71.9m
A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
TCRX
US$1.37
7D
-8.7%
1Y
-82.9%
I-Mab
Market Cap: US$71.7m
A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
IMAB
US$0.94
7D
10.5%
1Y
-47.8%
Surrozen
Market Cap: US$70.9m
A biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
SRZN
US$8.00
7D
-22.0%
1Y
-22.3%
RaQualia Pharma
Market Cap: JP¥10.5b
Engages in the research and development of pharmaceutical compounds worldwide.
4579
JP¥428.00
7D
2.4%
1Y
-26.1%
Context Therapeutics
Market Cap: US$70.1m
A biopharmaceutical company, develops products for the treatment of solid tumors.
CNTX
US$0.78
7D
-7.0%
1Y
-53.6%
Alterity Therapeutics
Market Cap: AU$109.5m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.012
7D
20.0%
1Y
140.0%
Adlai Nortye
Market Cap: US$68.3m
A clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
ANL
US$1.89
7D
-6.7%
1Y
-85.5%
Cantourage Group
Market Cap: €61.2m
Operates as a medical cannabis company in Europe.
HIGH
€4.91
7D
0.2%
1Y
-31.3%
Jasper Therapeutics
Market Cap: US$67.9m
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
JSPR
US$4.74
7D
-9.4%
1Y
-77.2%
IGM Biosciences
Market Cap: US$67.5m
A biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
IGMS
US$1.19
7D
-7.8%
1Y
-87.2%
Medexus Pharmaceuticals
Market Cap: CA$94.2m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.73
7D
0.7%
1Y
64.5%